• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    PureTech Health plc - American Depositary Shares (NQ:PRTC)

    17.54 UNCHANGED
    Streaming Delayed Price Updated: 1:45 PM EDT, Oct 16, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 17.54
    Bid (Size) 17.19 (1)
    Ask (Size) 17.85 (1)
    Prev. Close 17.54
    Today's Range 17.54 - 17.54
    52wk Range 13.30 - 24.99
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
    From PureTech Health plc
    Via Business Wire
    CoreWeave, Barrick Mining, FedEx And Other Big Stocks Moving Higher On Friday
     
    Via Benzinga

    Performance

    YTD
    -10.0%
    -10.0%
    1 Month
    +19.3%
    +19.3%
    3 Month
    -5.2%
    -5.2%
    6 Month
    +4.7%
    +4.7%
    1 Year
    -12.9%
    -12.9%

    More News

    Read More
    PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers
    From PureTech Health plc
    Via Business Wire
    Earnings Scheduled For April 30, 2025
    Via Benzinga
    PureTech (PRTC) Q2 2025 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    PureTech Health Cash Runway Extended
    Via The Motley Fool
    Earnings Scheduled For August 28, 2025
    Via Benzinga
    PureTech Health plc – Half-Year Report
    From PureTech Health plc
    Via Business Wire
    PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
    From PureTech Health plc
    Via Business Wire
    PureTech Health: Notice of Half-Yearly Results
    From PureTech Health plc
    Via Business Wire
    PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
    From PureTech Health plc
    Via Business Wire
    PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
    From PureTech Health plc
    Via Business Wire
    PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
    From PureTech Health plc
    Via Business Wire
    PureTech Announces Leadership Transition
    From PureTech Health plc
    Via Business Wire
    PureTech Announces Board Change
    From PureTech Health plc
    Via Business Wire
    Why This Biotech Stock Just Doubled In A Single Day
    Via Benzinga
    PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
    From PureTech Health plc
    Via Business Wire
    PureTech Health: Results of Annual General Meeting
    From PureTech Health plc
    Via Business Wire
    PureTech to Present at the Jefferies Global Healthcare Conference
    From PureTech Health plc
    Via Business Wire
    PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
    From PureTech
    Via Business Wire
    PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)
    From PureTech Health plc
    Via Business Wire
    PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
    From PureTech Health plc
    Via Business Wire
    PureTech Announces Annual Results for Year Ended December 31, 2024
    From PureTech Health plc
    Via Business Wire
    PureTech Health: Notice of Results
    From PureTech Health plc
    Via Business Wire
    PureTech Appoints Peel Hunt as Joint UK Corporate Broker
    From PureTech Health plc
    Via Business Wire

    Frequently Asked Questions

    Is PureTech Health plc - American Depositary Shares publicly traded?
    Yes, PureTech Health plc - American Depositary Shares is publicly traded.
    What exchange does PureTech Health plc - American Depositary Shares trade on?
    PureTech Health plc - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for PureTech Health plc - American Depositary Shares?
    The ticker symbol for PureTech Health plc - American Depositary Shares is PRTC on the Nasdaq Stock Market
    What is the current price of PureTech Health plc - American Depositary Shares?
    The current price of PureTech Health plc - American Depositary Shares is 17.54
    When was PureTech Health plc - American Depositary Shares last traded?
    The last trade of PureTech Health plc - American Depositary Shares was at 10/16/25 01:45 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.